Publications

Published articles:

Diagnosis and treatment of autoimmune hepatitis.

Verwer BJ, Bouma G, Bloemena E, Schreuder TC, Mulder CJ, van Nieuwkerk KM

Ned Tijdschr Geneeskd. 2009;153 (article in dutch)


The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes.

Baven-Pronk AM, Coenraad MJ, van Buuren HR, de Man RA, van Erpecum KJ, Lamers MM, Drenth JP, van den Berg AP, Beuers UH, den Ouden J, Koek GH, van Nieuwkerk CM, Bouma G, Brouwer JT, van Hoek B.

Aliment Pharmacol Ther 2011 Jun 12. 1365-2036


Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials.

Lamers MM, van Oijen MG, Pronk M, Drenth JP. 

J Hepatol. 2010 Jul;53(1):191-8


Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands.

van Gerven NM, Verwer BJ, Witte BI, van Erpecum KJ, van Buuren HR, Maijers I, Visscher AP, Verschuren EC, van Hoek B, Coenraad MJ, Beuers UH, de Man RA, Drenth JP, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Vrolijk JM, Mulder CJ, van Nieuwkerk CM, Bouma G; Dutch Autoimmune hepatitis STUDY group.

Scand J Gastroenterol. 2014 Oct;49(10):1245-54


Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission.

van Gerven NM, Verwer BJ, Witte BI, van Hoek B, Coenraad MJ, van Erpecum KJ, Beuers U, van Buuren HR, de Man RA, Drenth JP, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Mulder CJ, van Nieuwkerk KM, Bouma G; Dutch Autoimmune Hepatitis Working Group.

J Hepatol. 2013 Jan;58(1):141-7


 

Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis.

de Boer YS, van Gerven NM, de Boer NK, Mulder CJ, Bouma G, van Nieuwkerk CM.

Aliment Pharmacol Ther. 2013 Mar;37(6):640-6


Cytotoxic T lymphocyte antigen-4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis.

van Gerven NM, de Boer YS, Zwiers A, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, Drenth JP, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Vrolijk JM, Kraal G, Mulder CJ, van Nieuwkerk CM, Bouma G; Dutch Autoimmune Hepatitis Study group.

Liver Int. 2013 Aug;33(7):1039-43

 


Genome-wide association study identifies variants associated with autoimmune hepatitis type 1.

de Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, Drenth JP, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Vrolijk JM, Kraal G, Mulder CJ, van Nieuwkerk CM, Fischer J, Berg T, Stickel F, Sarrazin C, Schramm C, Lohse AW, Weiler-Normann C, Lerch MM, Nauck M, Völzke H, Homuth G, Bloemena E, Verspaget HW, Kumar V, Zhernakova A, Wijmenga C, Franke L, Bouma G; Dutch Autoimmune Hepatitis Study Group; LifeLines Cohort Study; Study of Health in Pomerania.

Gastroenterology. 2014 Aug;147(2):443-52


Seroprevalence of celiac disease in patients with autoimmune hepatitis.

van Gerven NM, Bakker SF, de Boer YS, Witte BI, Bontkes H, van Nieuwkerk CM, Mulder CJ, Bouma G; Dutch AIH working group.

Eur J Gastroenterol Hepatol. 2014 Oct;26(10):1104-7


HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1.

van Gerven NM, de Boer YS, Zwiers A, Verwer BJ, Drenth JP, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Vrolijk JM, Coenraad MJ, Kraal G, Mulder CJ, van Nieuwkerk CM, Bloemena E, Verspaget HW, Kumar V, Zhernakova A, Wijmenga C, Franke L, Bouma G; and The Dutch Autoimmune Hepatitis Study Group.

Genes Immun. 2015 Jan 22


Assessment of the histopathological key features in autoimmune hepatitis.

de Boer YS, van Nieuwkerk CM, Witte BI, Mulder CJ, Bouma G, Bloemena E.

Histopathology. 2015 Feb;66(3):351-62

Poster / Oral presentations:

1. Epidemiology of Autoimmune hepatitis in the Netherlands: A nationwide study
N.M.F. van Gerven et al.
Poster presentation Digestive Disease Week 05/2011, Chicago, USA
Oral presentation NVGE 03/2011, Veldhoven, the Netherlands

2. Maintenance treatment is necessary even when auto immune hepatitis is in remission. N.M.F. van Gerven et al.
Poster presentation Digestive Disease Week 05/2011, Chicago, USA
Oral presentation NVGE 03/2011, Veldhoven, the Netherlands